Drug Trial Radar · NCT05588531
Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Dec 20, 2021
Primary completion
Apr 2, 2022
Study completion Apr 8, 2022
Sponsor
- Lead sponsor
- Nanjing Yoko Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of multiple doses of YK-1169 in healthy subjects, the pharmacokinetic characteristics of multiple doses in healthy subjects, and the drug interaction between cefepime and avibactam.
Conditions
- Pharmacokinetics
Interventions
Group 1:YK-1169Drug
YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
Group 2:YK-1169/Placebo InjectionDrug
YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
Group 3:YK-1169/PlaceboDrug
On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Group 4:YK-1169/PlaceboDrug
On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
Group 5:YK-1169/Placebo InjectionDrug
YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injectionDrug
YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- According to Common Terminology Criteria for Adverse Events Version 5.0, the incidence and frequency of AEs and SAEs will be statistically analyzedTime frame: Through study completion, an average of 1 month.
- clinical adverse eventsTime frame: Through study completion, an average of 1 month.
- body temperature (frontal temperature)Time frame: Through study completion, an average of 1 month.
- PulseTime frame: Through study completion, an average of 1 month.
- sitting blood pressureTime frame: Through study completion, an average of 1 month.
- physical examinationTime frame: Through study completion, an average of 1 month.
- laboratory testsTime frame: Through study completion, an average of 1 month.
- 12-lead ECGTime frame: Through study completion, an average of 1 month.
- premature withdrawalTime frame: Through study completion, an average of 1 month.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
辛玉霞
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.